Protopic Use in One-Year-Olds: Not FDA-Approved
Protopic (tacrolimus) is not approved for use in children under 2 years of age, and should not be used in a one-year-old for atopic dermatitis. 1, 2
FDA-Approved Age Restrictions
- Topical tacrolimus 0.03% ointment is FDA-approved only for patients 2 years of age and older with atopic dermatitis 1
- The Taiwan Academy of Pediatric Allergy, Asthma and Immunology guidelines similarly restrict topical calcineurin inhibitors (including tacrolimus) to patients aged 2 years and above 2
Off-Label Use Reality and Concerns
Despite the age restriction, there has been significant off-label use in younger children:
- Approximately half a million prescriptions were written for children less than 2 years of age between June 2003 and May 2004, demonstrating widespread off-label use 3
- However, this off-label use occurred without adequate absorption and safety studies in infants and young children 3
- Additional absorption studies are specifically needed in infants and young children before use can be recommended 3
Appropriate Treatment for One-Year-Olds
For a one-year-old with atopic dermatitis, use these FDA-approved alternatives:
- Low-potency topical corticosteroids are the first-line treatment for flares in infants and young children 2, 4
- Infants should be treated with less potent topical corticosteroids than older children due to increased risk of adrenal suppression 2
- Regular application of fragrance-free emollients to maintain skin barrier integrity 4
- Avoid high-potency topical corticosteroids on sensitive areas (face, neck, skin folds) to prevent skin atrophy 2, 4
Common Pitfall to Avoid
Do not use Protopic as a "steroid-sparing" agent in children under 2 years, even though this perception has driven increased off-label use 3. The safety profile in this age group remains inadequately studied, and FDA-approved alternatives (low-potency topical corticosteroids with proper application technique) are both safe and effective for this population 2, 4.